Laughren T - Search Results

1

Essential pharmacokinetic information for drug dosage decisions: a concise visual presentation in the drug label.

Menon-Andersen D, Yu B, Madabushi R, Bhattaram V, Hao W, Uppoor RS, Mehta M, Lesko L, Temple R, Stockbridge N, Laughren T, Gobburu JV. Menon-Andersen D, et al. Among authors: laughren t. Clin Pharmacol Ther. 2011 Sep;90(3):471-4. doi: 10.1038/clpt.2011.149. Epub 2011 Jul 27. Clin Pharmacol Ther. 2011. PMID: 21796114 No abstract available.

2

Removal from labeling of 60-mg citalopram dose.

Temple R, Laughren T, Stockbridge N. Temple R, et al. Among authors: laughren t. Pharmacoepidemiol Drug Saf. 2012 Jul;21(7):784-786. doi: 10.1002/pds.3289. Pharmacoepidemiol Drug Saf. 2012. PMID: 22761131 No abstract available.

3

An integrated approach for establishing dosing recommendations: paliperidone for the treatment of adolescent schizophrenia.

Younis IR, Laughren TP, Wang Y, Mathis M, Gobburu JV. Younis IR, et al. J Clin Psychopharmacol. 2013 Apr;33(2):152-6. doi: 10.1097/JCP.0b013e31828393a8. J Clin Psychopharmacol. 2013. PMID: 23422374 Clinical Trial.

4

Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant.

Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, Dinh PV, Fossom L, Hung HM, Klimek V, Lee JE, Levin RL, Lindberg CY, Mathis M, Rosloff BN, Wang SJ, Wang Y, Yang P, Yu B, Zhang H, Zhang L, Zineh I. Laughren TP, et al. J Clin Psychiatry. 2011 Sep;72(9):1166-73. doi: 10.4088/JCP.11r06984. J Clin Psychiatry. 2011. PMID: 21951984 Review.

5

CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations.

Rogers HL, Bhattaram A, Zineh I, Gobburu J, Mathis M, Laughren TP, Pacanowski M. Rogers HL, et al. J Clin Psychiatry. 2012 Sep;73(9):1187-90. doi: 10.4088/JCP.11m07572. J Clin Psychiatry. 2012. PMID: 23059146

6

Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration.

Borges S, Chen YF, Laughren TP, Temple R, Patel HD, David PA, Mathis M, Unger E, Yang P, Khin NA. Borges S, et al. Among authors: laughren tp. J Clin Psychiatry. 2014 Mar;75(3):205-14. doi: 10.4088/JCP.13r08722. J Clin Psychiatry. 2014. PMID: 24717376 Review.

7

Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration.

Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G. Stone M, et al. Among authors: laughren t. BMJ. 2009 Aug 11;339:b2880. doi: 10.1136/bmj.b2880. BMJ. 2009. PMID: 19671933 Free PMC article. Review.

8

Premarketing studies in the drug approval process: understanding their limitations regarding the assessment of drug safety.

Laughren T. Laughren T. Clin Ther. 1998;20 Suppl C:C12-9. doi: 10.1016/s0149-2918(98)80003-9. Clin Ther. 1998. PMID: 9915085 Review.

9

Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment.

Bruno CD, Elmokadem A, Housand C, Jordie EB, Chow CR, Laughren TP, Greenblatt DJ. Bruno CD, et al. Among authors: laughren tp. J Clin Pharmacol. 2022 Jan;62(1):55-65. doi: 10.1002/jcph.1947. Epub 2021 Aug 26. J Clin Pharmacol. 2022. PMID: 34339048

10

What's next after 50 years of psychiatric drug development: an FDA perspective.

Laughren TP. Laughren TP. J Clin Psychiatry. 2010 Sep;71(9):1196-204. doi: 10.4088/JCP.10m06262gry. J Clin Psychiatry. 2010. PMID: 20923624

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

66 results

Search Page

Filters